Akcea to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
December 07 2017 - 7:00AM
Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis
Pharmaceuticals, Inc., focused on developing and commercializing
drugs to treat patients with serious cardiometabolic diseases
caused by lipid disorders, today announced that management will
present a company overview at the BMO Capital Markets 2017
Prescriptions for Success Healthcare Conference at 10:30 a.m. ET on
Thursday, December 14, 2017 in New York, NY.
A live webcast of the presentation will be available on the
“Media & Investors” section at www.akceatx.com. The replay will
be available within 48 hours and will be archived for a limited
time.
ABOUT AKCEA THERAPEUTICSAkcea Therapeutics, an
affiliate of Ionis Pharmaceuticals, Inc., is a biopharmaceutical
company focused on developing and commercializing drugs to treat
patients with serious cardiometabolic diseases caused by lipid
disorders. Akcea is advancing a mature pipeline of four novel
drugs, including volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx
and AKCEA-APOCIII-LRx, all with the potential to treat multiple
diseases. All four drugs were discovered by and are being
co-developed with Ionis, a leader in antisense therapeutics, and
are based on Ionis’ proprietary antisense technology. The most
advanced drug in its pipeline, volanesorsen, is under regulatory
review in the U.S., EU and Canada for the treatment of familial
chylomicronemia syndrome, or FCS, and is currently in Phase 3
clinical development for the treatment of familial partial
lipodystrophy, or FPL. Akcea is building the infrastructure to
commercialize its drugs globally with a focus on lipid specialists
as the primary call point. Akcea is located in Cambridge,
Massachusetts. Additional information about Akcea is available at
www.akceatx.com.
FORWARD-LOOKING STATEMENTThis press release
includes forward-looking statements regarding the business of Akcea
Therapeutics, Inc. and the therapeutic and commercial potential of
volanesorsen and other products in development. Any statement
describing Akcea’s goals, expectations, financial or other
projections, intentions or beliefs is a forward-looking statement
and should be considered an at-risk statement. Such statements are
subject to certain risks and uncertainties, particularly those
inherent in the process of discovering, developing and
commercializing drugs that are safe and effective for use as human
therapeutics, and in the endeavor of building a business around
such drugs. Akcea’s forward-looking statements also involve
assumptions that, if they never materialize or prove correct, could
cause its results to differ materially from those expressed or
implied by such forward-looking statements. Although Akcea’s
forward-looking statements reflect the good faith judgment of its
management, these statements are based only on facts and factors
currently known by Akcea. As a result, you are cautioned not to
rely on these forward-looking statements. These and other risks
concerning Akcea’s programs are described in additional detail in
its final prospectus for its initial public offering and its most
recent quarterly report on Form 10-Q, which is on file with the
SEC.
In this press release, unless the context requires otherwise,
“Ionis”, “Akcea,” “Company,” “Companies” “we,” “our,” and “us”
refers to Ionis Pharmaceuticals and/or Akcea Therapeutics.
Ionis Pharmaceuticals™ is a trademark of Ionis Pharmaceuticals,
Inc. Akcea Therapeutics™ is a trademark of Ionis Pharmaceuticals,
Inc.
Media and Investor Contacts:Kathleen
GallagherExecutive Director, Corporate Communications and Investor
Relations617-207-8509kgallagher@akceatx.com
Akcea Therapeutics (NASDAQ:AKCA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akcea Therapeutics (NASDAQ:AKCA)
Historical Stock Chart
From Apr 2023 to Apr 2024